纳斯达克 · 生物技术 · USD
AgomAb Therapeutics NV (AGMB) 股票分析
AgomAb Therapeutics NV（AGMB）是在纳斯达克上市的生物技术股票，以美元交易。
最后更新: 2026年10月21日
价格走势
暂无价格数据
悬停查看每日收盘价。虚线表示区间起始价。
AGMB 关键统计数据
数据截至2026年10月21日交易
- 开盘价
- $8.74
- 前收盘价
- $8.73
- 当日波动区间
- 8.74–9.22
- 52周波动区间
- 7.92–17.82
- 成交量
- 4.24万
估值
- 市值
- $4.49亿
- 市盈率
- 亏损
- 每股收益（近12个月）过去十二个月归属于每股的利润。
- −2.08
财务（财年）
- 营业收入（财年）
- $0.00
- 净利润（财年）
- −$6254.70万
- 流通股数
- 4924.80万
股息与日期
- 平均成交量
- 13.76万
仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。
关键数据
AgomAb Therapeutics NV（AGMB）的市值为$4.49亿。
2025财年，AGMB的营业收入为$0.00。
AGMB 各财年营收与利润
财年截至十二月营业收入净利润
2022202320242025
| 财年 | 营业收入 | 净利润 | 净利率 |
|---|---|---|---|
| 2025 | $0.00 | −$6254.70万 | — |
| 2024 | $0.00 | −$4626.70万 | — |
| 2023 | $0.00 | −$1139.00万 | — |
| 2022 | $0.00 | −$814.20万 | — |
| 财年 | 营业收入 | 毛利 | 营业利润 | 净利润 | 净利率 |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$5927.50万 | −$6254.70万 | — |
| 2024 | $0.00 | — | −$4802.10万 | −$4626.70万 | — |
| 2023 | $0.00 | — | −$3119.00万 | −$1139.00万 | — |
| 2022 | $0.00 | — | −$2263.40万 | −$814.20万 | — |
为公司报告货币口径的年度公布数据。 数据截至2025年12月31日。
最新新闻
Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease
YahooAgomab Therapeutics Doses First Patient In NOV-ERA, Global Phase 2b Study Evaluating Ontunisertib In Patients With Symptomatic FSCD
BenzingaAgomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation
YahooAgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn's Disease Transcript
SeekingAlphaAgomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
BenzingaAgomab stock jumps on positive trial data
Yahoo
全部17篇文章 ↓收起 ↑
Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease
YahooAgomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%
BenzingaAgomAb Therapeutics: Building A New Treatment Layer In Fibrosis
SeekingAlphaAgomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
YahooAgomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
YahooThis Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
BenzingaPiper Sandler Initiates Coverage On AgomAb Therapeutics with Overweight Rating, Announces Price Target of $60
BenzingaCantor Fitzgerald Initiates Coverage On AgomAb Therapeutics with Overweight Rating
BenzingaAgomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
YahooAgomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
YahooAgomAb Therapeutics H1 EPS $(0.93)
Benzinga
新闻由第三方来源提供。不构成投资建议。
分析
数据生成以上所有数字均在每日重新生成时从本页自身的数据中读取。仅供参考，不构成投资建议。 数据截至2026年10月21日。
相关生物技术股票
VRTX
查看所有生物技术股票 →
Vertex Pharmaceuticals Incorporated
$1329.45亿
MRNAModerna, Inc.
$981.36亿
REGNRegeneron Pharmaceuticals, Inc.
$829.48亿
ARGXargenx SE
$559.72亿
ONCBeOne Medicines AG
$439.67亿
RVMDRevolution Medicines, Inc.
$416.41亿
医疗保健热门股票
LLY
查看所有医疗保健股票 →
Eli Lilly and Company
$1.13万亿
JNJJohnson & Johnson
$6212.24亿
ABBVAbbVie Inc.
$5032.75亿
UNHUnitedHealth Group Incorporated
$3742.97亿
MRKMerck & Co., Inc.
$3697.80亿